AVDL vs HSIC · rev $169.1M vs P/E 24, rev $6.83B
Avadel Pharmaceuticals PLC (AVDL) versus Henry Schein Inc (HSIC) — a side-by-side from cached financials, not a winner call.
Avadel Pharmaceuticals PLC (AVDL) is a drug manufacturers - specialty & generic company listed on US.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Latest reported AVDL revenue for 2024-12-31 was $169.1M. Net income was -$48.8M. Revenue was up 504.8% from 2023-12-31 to 2024-12-31. AVDL currently screens at market cap $968.5M.
Latest reported HSIC revenue for 2026-06-27 was $6.83B. Net income was $201.0M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
AVDL currently screens at market cap $968.5M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Not investment advice. Open the AVDL and HSIC stock pages for the full models.
Not investment advice.